Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Seung-Jae Lee 3 Articles
Modeling α-Synuclein Propagation with Preformed Fibril Injections
Hyun Kyung Chung, Hoang-Anh Ho, Dayana Pérez-Acuña, Seung-Jae Lee
J Mov Disord. 2020;13(1):77-79.   Published online October 14, 2019
DOI: https://doi.org/10.14802/jmd.19046.e
Corrects: J Mov Disord 2019;12(3):139
  • 4,043 View
  • 113 Download
  • 5 Citations
PDF

Citations

Citations to this article as recorded by  
  • Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease
    Rui Huang, Yuyuan Gao, Qingrui Duan, Qingxi Zhang, Peikun He, Jianing Chen, Guixian Ma, Limin Wang, Yuhu Zhang, Kun Nie, Lijuan Wang
    Molecular Neurobiology.2023; 60(2): 979.     CrossRef
  • Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets
    Smrithi Padmakumar, Praveen Kulkarni, Craig F. Ferris, Benjamin S. Bleier, Mansoor M. Amiji
    Biomedicine & Pharmacotherapy.2022; 149: 112812.     CrossRef
  • Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound
    Rodrigo Tomas-Grau, Florencia González-Lizárraga, Diego Ploper, César L. Avila, Sergio B. Socías, Pierre Besnault, Aurore Tourville, Rosa M. Mella, Patricia Villacé, Clarisa Salado, Clémence Rose, Blandine Seon-Méniel, Jean-Michel Brunel, Laurent Ferrié,
    Cells.2022; 11(17): 2759.     CrossRef
  • Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction
    Renee C Gentzel, Dawn Toolan, Sarah Jinn, Joel B Schachter, Lei Ma, Philipp J Kahle, Sean M Smith, Jacob N Marcus
    Neurobiology of Aging.2021; 106: 12.     CrossRef
  • Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson’s Disease Risk
    Alix Booms, Gerhard A. Coetzee
    Frontiers in Cellular Neuroscience.2021;[Epub]     CrossRef
Modeling α-Synuclein Propagation with Preformed Fibril Injections
Hyun Kyung Chung, Hoang-Anh Ho, Dayana Pérez-Acuña, Seung-Jae Lee
J Mov Disord. 2019;12(3):139-151.   Published online September 30, 2019
DOI: https://doi.org/10.14802/jmd.19046
Correction in: J Mov Disord 2020;13(1):77
  • 11,890 View
  • 738 Download
  • 35 Citations
AbstractAbstract PDF
The aggregation of α-synuclein (α-syn) has been implicated in the pathogenesis of many neurodegenerative disorders, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Postmortem analyses of α-syn pathology, especially that of PD, have suggested that aggregates progressively spread from a few discrete locations to wider brain regions. The neuron-to-neuron propagation of α-syn has been suggested to be the underlying mechanism by which aggregates spread throughout the brain. Many cellular and animal models has been created to study cell-to-cell propagation. Recently, it has been shown that a single injection of preformed fibrils (PFFs) made of recombinant α-syn proteins into various tissues and organs of many different animal species results in widespread α-syn pathology in the central nervous system (CNS). These PFF models have been extensively used to study the mechanism by which aggregates spread throughout the brain. Here, we review what we have learned from PFF models, describe the nature of PFFs and the neuropathological features, neurophysiological characteristics, and behavioral outcomes of the models.

Citations

Citations to this article as recorded by  
  • CSF-derived extracellular vesicles from patients with Parkinson’s disease induce symptoms and pathology
    Shay Herman, Ruth Djaldetti, Brit Mollenhauer, Daniel Offen
    Brain.2023; 146(1): 209.     CrossRef
  • DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation
    Sora Kang, Ying Piao, Young Cheol Kang, Suyeol Lim, Youngmi Kim Pak
    Biomedicine & Pharmacotherapy.2022; 145: 112389.     CrossRef
  • Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells
    Eftychia Vasili, Antonio Dominguez-Meijide, Manuel Flores-León, Mohammed Al-Azzani, Angeliki Kanellidi, Ronald Melki, Leonidas Stefanis, Tiago Fleming Outeiro
    Molecular Neurobiology.2022; 59(2): 1273.     CrossRef
  • Phosphorylation of endogenous α-synuclein induced by extracellular seeds initiates at the pre-synaptic region and spreads to the cell body
    Shiori Awa, Genjiro Suzuki, Masami Masuda-Suzukake, Takashi Nonaka, Minoru Saito, Masato Hasegawa
    Scientific Reports.2022;[Epub]     CrossRef
  • Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
    Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim
    Journal of Movement Disorders.2022; 15(1): 1.     CrossRef
  • α-Synuclein in Parkinson's disease and advances in detection
    Rong Chen, Xuan Gu, Xiaoying Wang
    Clinica Chimica Acta.2022; 529: 76.     CrossRef
  • Neurons with Cat’s Eyes: A Synthetic Strain of α-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions
    Francesca De Giorgi, Muhammed Bilal Abdul-Shukkoor, Marianna Kashyrina, Leslie-Ann Largitte, Francesco De Nuccio, Brice Kauffmann, Alons Lends, Florent Laferrière, Sébastien Bonhommeau, Dario Domenico Lofrumento, Luc Bousset, Erwan Bezard, Thierry Buffete
    Biomolecules.2022; 12(3): 436.     CrossRef
  • A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models
    Anurupa A. Ghosh, Dinesh Kumar Verma, Gabriela Cabrera, Kwadwo Ofori, Karina Hernandez-Quijada, Jae-Kwan Kim, Joo Hee Chung, Michael Moore, Sung Hwan Moon, Jong Bok Seo, Yong-Hwan Kim
    International Journal of Molecular Sciences.2022; 23(8): 4262.     CrossRef
  • Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease
    Carmen Costas, Lilian R.F. Faro
    Current Neuropharmacology.2022; 20(2): 432.     CrossRef
  • NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson’s disease
    Min Kyung Song, Levi Adams, Joo Hee Lee, Yoon-Seong Kim, Hemant K. Paudel
    PLOS ONE.2022; 17(7): e0272085.     CrossRef
  • Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo
    Rachel E. Lackie, Aline S. de Miranda, Mei Peng Lim, Vladislav Novikov, Nimrod Madrer, Nadun C. Karunatilleke, Benjamin S. Rutledge, Stephanie Tullo, Anne Brickenden, Matthew E. R. Maitland, David Greenberg, Daniel Gallino, Wen Luo, Anoosha Attaran, Irina
    Acta Neuropathologica.2022; 144(5): 881.     CrossRef
  • Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes
    Francisco J. Padilla-Godínez, Leonardo I. Ruiz-Ortega, Magdalena Guerra-Crespo
    Cells.2022; 11(21): 3445.     CrossRef
  • Overexpression-Induced α-Synuclein Brain Spreading
    Rita Pinto-Costa, Eugenia Harbachova, Pietro La Vitola, Donato A. Di Monte
    Neurotherapeutics.2022;[Epub]     CrossRef
  • Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
    Andreza Fabro de Bem, Rachel Krolow, Hémelin Resende Farias, Victória Linden de Rezende, Daniel Pens Gelain, José Cláudio Fonseca Moreira, João Miguel das Neves Duarte, Jade de Oliveira
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Role of Liver Growth Factor (LGF) in Parkinson’s Disease: Molecular Insights and Therapeutic Opportunities
    Efthalia Angelopoulou, Yam Nath Paudel, Christina Piperi
    Molecular Neurobiology.2021; 58(7): 3031.     CrossRef
  • Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain
    Nelson Ferreira, Nádia Pereira Gonçalves, Asad Jan, Nanna Møller Jensen, Amelia van der Laan, Simin Mohseni, Christian Bjerggaard Vægter, Poul Henning Jensen
    Acta Neuropathologica Communications.2021;[Epub]     CrossRef
  • Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation
    Omid Tavassoly, Esther del Cid Pellitero, Frederique Larroquette, Eddie Cai, Rhalena A. Thomas, Vincent Soubannier, Wen Luo, Thomas M. Durcan, Edward A. Fon
    Neurotherapeutics.2021; 18(2): 979.     CrossRef
  • The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
    Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, Grace Auld, Sonia Gandhi, Thomas Foltynie
    Drugs & Aging.2021; 38(5): 355.     CrossRef
  • Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy
    Nelson Ferreira, Mette Richner, Amelia van der Laan, Ida Bergholdt Jul Christiansen, Christian B Vægter, Jens R Nyengaard, Glenda M Halliday, Joachim Weis, Benoit I Giasson, Ian R Mackenzie, Poul H Jensen, Asad Jan
    Brain Communications.2021;[Epub]     CrossRef
  • Impact of the apelin/APJ axis in the pathogenesis of Parkinson’s disease with therapeutic potential
    Efthalia Angelopoulou, Yam Nath Paudel, Anastasia Bougea, Christina Piperi
    Journal of Neuroscience Research.2021; 99(9): 2117.     CrossRef
  • Adenovirus-induced Reactive Astrogliosis Exacerbates the Pathology of Parkinson’s Disease
    Heeyoung An, Hyowon Lee, Seulkee Yang, Woojin Won, C. Justin Lee, Min-Ho Nam
    Experimental Neurobiology.2021; 30(3): 222.     CrossRef
  • Brain iron enrichment attenuates α‐synuclein spreading after injection of preformed fibrils
    Karina Dauer née Joppe, Lars Tatenhorst, Lucas Caldi Gomes, Shuyu Zhang, Mojan Parvaz, Eleonora Carboni, Anna‐Elisa Roser, Hazem El DeBakey, Mathias Bähr, Katarina Vogel‐Mikuš, Chi Wang Ip, Stefan Becker, Markus Zweckstetter, Paul Lingor
    Journal of Neurochemistry.2021; 159(3): 554.     CrossRef
  • Increased oscillatory power in a computational model of the olfactory bulb due to synaptic degeneration
    J. Kendall Berry, Daniel Cox
    Physical Review E.2021;[Epub]     CrossRef
  • Combining Automated Organoid Workflows with Artificial Intelligence‐Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High‐Throughput Screens for Parkinson's Disease and Beyond
    Henrik Renner, Hans R. Schöler, Jan M. Bruder
    Movement Disorders.2021; 36(12): 2745.     CrossRef
  • Is Multiple System Atrophy a Prion-like Disorder?
    Kurt A. Jellinger, Gregor K. Wenning, Nadia Stefanova
    International Journal of Molecular Sciences.2021; 22(18): 10093.     CrossRef
  • Cortical alpha-synuclein preformed fibrils do not affect interval timing in mice
    Qiang Zhang, Hisham Abdelmotilib, Travis Larson, Cameron Keomanivong, Mackenzie Conlon, Georgina M. Aldridge, Nandakumar S. Narayanan
    Neuroscience Letters.2021; 765: 136273.     CrossRef
  • Temporal Evolution of Inflammation and Neurodegeneration With Alpha-Synuclein Propagation in Parkinson's Disease Mouse Model
    Thuy Thi Lai, Yun Joong Kim, Phuong Thi Nguyen, Young Ho Koh, Tinh Thi Nguyen, Hyeo-il Ma, Young Eun Kim
    Frontiers in Integrative Neuroscience.2021;[Epub]     CrossRef
  • The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders
    Katja Malfertheiner, Nadia Stefanova, Antonio Heras-Garvin
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • A historical review of multiple system atrophy with a critical appraisal of cellular and animal models
    David J. Marmion, Wouter Peelaerts, Jeffrey H. Kordower
    Journal of Neural Transmission.2021; 128(10): 1507.     CrossRef
  • Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines
    Masaru Tanaka, József Toldi, László Vécsei
    International Journal of Molecular Sciences.2020; 21(7): 2431.     CrossRef
  • Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
    Mónica Gómez-Benito, Noelia Granado, Patricia García-Sanz, Anne Michel, Mireille Dumoulin, Rosario Moratalla
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Rose B. Creed, Matthew S. Goldberg
    Neuroscience.2020; 437: 64.     CrossRef
  • Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of α-Synuclein
    Yuan Guan, Xiaofang Zhao, Fengwei Liu, Shuxin Yan, Yalong Wang, Cuilian Du, Xiuyu Cui, Rena Li, Claire Xi Zhang
    Frontiers in Cellular Neuroscience.2020;[Epub]     CrossRef
  • Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes
    Alessia Indrieri, Rocco Pizzarelli, Brunella Franco, Elvira De Leonibus
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Classic and evolving animal models in Parkinson's disease
    Tanvi Pingale, Girdhari Lal Gupta
    Pharmacology Biochemistry and Behavior.2020; 199: 173060.     CrossRef
Mechanism of Anti-α-Synuclein Immunotherapy
Jun Sung Lee, Seung-Jae Lee
J Mov Disord. 2016;9(1):14-19.   Published online January 25, 2016
DOI: https://doi.org/10.14802/jmd.15059
  • 23,461 View
  • 307 Download
  • 33 Citations
AbstractAbstract PDF
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.

Citations

Citations to this article as recorded by  
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
    Shin Hye Noh, Ye Jin Kim, Min Goo Lee
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
    Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
    Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
    Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593.     CrossRef
  • Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
    Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
    Immunology.2021; 162(2): 160.     CrossRef
  • Electrogastrography for diagnosis of early-stage Parkinson's disease
    Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
    Parkinsonism & Related Disorders.2021; 86: 61.     CrossRef
  • Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
    Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
    Molecules.2021; 26(12): 3736.     CrossRef
  • Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
    Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
    Neurochemical Research.2021; 46(12): 3123.     CrossRef
  • Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
    Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
    CNS & Neurological Disorders - Drug Targets .2021; 20(9): 802.     CrossRef
  • Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
    Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
    Pharmacological Reviews.2021; 73(4): 1204.     CrossRef
  • Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
    Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
    Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
    Translational Neurodegeneration.2020;[Epub]     CrossRef
  • Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
    James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
    Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
    Molecular Neurobiology.2019; 56(7): 4799.     CrossRef
  • The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
    Datis Kharrazian, Martha Herbert, Aristo Vojdani
    Toxics.2019; 7(2): 26.     CrossRef
  • Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model
    Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
    Alzheimer's & Dementia.2019; 15(9): 1133.     CrossRef
  • Translational therapies for multiple system atrophy: Bottlenecks and future directions
    Nadia Stefanova
    Autonomic Neuroscience.2018; 211: 7.     CrossRef
  • Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
    Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
    Redox Biology.2018; 14: 600.     CrossRef
  • Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
    Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
    Journal of Neuroimmunology.2018; 315: 33.     CrossRef
  • Beneficial Effects of Flavonoids Against Parkinson's Disease
    Un Ju Jung, Sang Ryong Kim
    Journal of Medicinal Food.2018; 21(5): 421.     CrossRef
  • Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
    Jiyoon Kim, Heon Yung Gee, Min Goo Lee
    Journal of Cell Science.2018;[Epub]     CrossRef
  • Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
    Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
    Frontiers in Neuroscience.2018;[Epub]     CrossRef
  • Gene therapy for neurological disorders: progress and prospects
    Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
    Nature Reviews Drug Discovery.2018; 17(9): 641.     CrossRef
  • Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
    Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
    Journal of Neural Transmission.2017; 124(6): 721.     CrossRef
  • Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
    Xiaoli Si, Jiali Pu, Baorong Zhang
    Journal of Movement Disorders.2017; 10(2): 69.     CrossRef
  • Membrane Trafficking Illuminates a Path to Parkinson’s Disease
    Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
    The Tohoku Journal of Experimental Medicine.2017; 242(1): 63.     CrossRef
  • Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
    J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
    Scientific Reports.2017;[Epub]     CrossRef
  • Impact of aging immune system on neurodegeneration and potential immunotherapies
    Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
    Progress in Neurobiology.2017; 157: 2.     CrossRef
  • A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
    Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
    PLOS ONE.2017; 12(9): e0184731.     CrossRef
  • Vaccination strategies in tauopathies and synucleinopathies
    Anne K. Braczynski, Jörg B. Schulz, Jan-Philipp Bach
    Journal of Neurochemistry.2017; 143(5): 467.     CrossRef
  • Missions of <italic>Journal of Movement Disorders</italic>
    Yun Joong Kim
    Journal of Movement Disorders.2016; 9(1): 1.     CrossRef
  • How strong is the evidence that Parkinson's disease is a prion disorder?
    Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
    Current Opinion in Neurology.2016; 29(4): 459.     CrossRef

JMD : Journal of Movement Disorders